What are the recommended medications for treating stomatitis in an adult?

Stomatitis Medication

For treating stomatitis in adults, start with sodium bicarbonate mouthwash (4-6 times daily, increasing to hourly if needed) combined with topical analgesics like viscous lidocaine 2% for pain control, and escalate to topical corticosteroids (dexamethasone 0.1 mg/ml mouth rinse or clobetasol 0.05% gel) for ulcerative lesions that don't respond to initial therapy. 1

Treatment Algorithm by Severity

Mild Stomatitis (No Ulcers)

• Bland non-alcoholic sodium bicarbonate mouthwash: 4-6 times daily for prevention, increase to hourly for active treatment 1
• Basic oral care protocols: Maintain meticulous oral hygiene 1
• Salivary management: If dry mouth present, use sugarless chewing gum, candy, or salivary substitutes 1

Moderate Stomatitis (Pain Without Severe Ulceration)

• Topical anesthetics: Viscous lidocaine 2% mouthwash for immediate pain relief 1
  • Apply before meals if eating is painful
  • Can use coating agents as adjuncts
• Topical NSAIDs: Amlexanox 5% oral paste for moderate pain 1
• Alternative: Dyclonine hydrochloride 1.0% provides effective pain relief lasting approximately 50 minutes 2
• Systemic analgesics: If topical measures insufficient, use acetaminophen (paracetamol) as maintenance therapy 1

Severe Stomatitis (Ulcerative Lesions)

First-line topical corticosteroids 1:

• Multiple or difficult-to-reach ulcers: Dexamethasone mouth rinse 0.1 mg/ml
• Localized, accessible ulcers: Clobetasol gel or ointment 0.05%

If ulcers don't resolve with topical steroids 1:

• Intralesional steroid injection: Triamcinolone weekly (total dose 28 mg) combined with topical clobetasol 0.05%

For highly symptomatic, recurrent, or esophageal lesions 1:

• Systemic corticosteroids: High-dose pulse prednisone/prednisolone 30-60 mg (or 1 mg/kg) for 1 week, then taper over second week

Severe Pain Management

• Moderate-severe pain: Consider immediate-release oral opioids or fast-acting fentanyl preparations (50 μg nasal spray) for short-term relief before meals 1
  • Note: Fast-acting fentanyl registered for opioid-tolerant patients but may be considered in this population
• Persistent severe pain: Use alternative administration routes (transdermal, intranasal) since oral administration may be compromised 1
• Patient-controlled analgesia with morphine: Recommended for stem cell transplant patients with severe mucositis 1

Context-Specific Considerations

Cancer Treatment-Related Stomatitis

The evidence provided primarily addresses cancer therapy-related stomatitis [1-1]. For this population:

• Low-level laser therapy (650 nm wavelength, 40 mW power, 2 J/cm² tissue energy dose) is recommended for prevention in high-dose chemotherapy/stem cell transplant settings 1
• Benzydamine mouthwash prevents oral mucositis in head/neck cancer patients receiving moderate-dose radiation (up to 50 Gy) without chemotherapy 1

Recurrent Aphthous Stomatitis (Non-Cancer)

For recurrent aphthous ulcers specifically 3:

• First-line: Topical corticosteroids remain the standard
• Emerging option: Topical doxycycline shows efficacy in promoting healing 4
• Novel therapy: Oral roflumilast (phosphodiesterase-4 inhibitor) demonstrates 88% reduction in flare-ups and 94% reduction in oral ulcers, though this is based on observational data 5
• Screen for nutritional deficiencies: Check vitamin B12, folic acid, and ferritin levels, as deficiencies are associated with recurrent aphthous stomatitis 3

Critical Pitfalls to Avoid

Avoid these interventions (evidence shows no benefit or harm):

• Sucralfate mouthwash for chemotherapy or radiation-induced stomatitis 1
• Chlorhexidine mouthwash for radiation therapy patients 1
• Systemic pentoxifylline, pilocarpine, or IV glutamine for prevention 1

Important caveats:

• If mouthwash causes pain, apply topical anesthetic first before using other rinses 1
• Most physician surveys reveal poor awareness of stomatitis management guidelines (61.3% unaware), highlighting the need for systematic approaches 6
• Treatment modifications (dose reduction/interruption/discontinuation) occur in 20-35% of cancer patients with stomatitis, emphasizing the importance of aggressive symptom management 6